Corpus overview


Overview

MeSH Disease

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    An Effective Inhaler Medication In The Treatment Of COVID-19 MESHD Associated Pneumonia 

    Authors: Oguz Guvenmez; Huseyin Keskin; Suayip Birinci; Semra Sardaş; Mehmet Salih Sevdi; Kanat Tayfun; Adnan Kazım Usalan; Mujgan Çalışkan; Mehmet Karabay; Burak Ay; Resat Duman; Nilay Duman; Asım Kayıklık; Mehmet Cubuk; Muhammed Furkan Kanca; Ayten Altıntaş; Ahmet Yaser Muslumanoglu

    doi:10.21203/rs.3.rs-53215/v2 Date: 2020-08-04 Source: ResearchSquare

    BackgroundCurrent COVID-19 MESHD treatment methods are in the form of oral tablets or intravenous therapy. However, even if the efficacy of these agents is shown in in-vitro studies, the same effect cannot be seen in in-vivo. This is because these treatments are intended to reach the lungs through the blood SERO. However, severe i nterstitial edema MESHD edema HP and blood SERO lood alveolar MESHDbarrier does not allow medications to reach the lungs effectively.ObjectiveIn the new inhaler treatment (N IT) MESHD given in this clinical study, the molecules that have antiviral, antioxidant and anti-inflammatory effects without any t oxicity MESHDwere brought together. This study aims to prevent rapid and effective clinical improvement in COVID-19 MESHD patients and prevent any complications related to COVID-19 MESHD i nfection. MESHDMethodsThis study approved by The Ministry of Health of Turkey. This clinical study was designed as a multi-center study and performed in Istanbul and Mersin, Turkey. The patients were divided into two groups. Patients were randomly assigned following simple randomization procedures. Eighty patients received the normal treatment protocol, while eighty patients received the new inhalation treatment protocol in addition to the normal treatment protocol. It was applied by connecting the T nebulizer device in intubated patients and with a nebulizer mask in non-intubated patients. Pulse oxygen saturation, respiratory rate, percentage of lung involvement, arterial blood SERO gas, and duration of hospitalization were compared after the treatment.ResultsOne of the most important points of this study is the duration of hospital stay between the two groups. The mean duration of hospitalization in group 1 was 6.5 ± 1.8; in group 2 it was 17.1 ± 2.4. The duration of stay in Group 1 was significantly lower than group 2. (P < 0.05) FOS (Finger oxygen saturation) values were 89.2 ± 4.8 and 96.1 ± 4.7 in group 1 at the end of the 3rd and 7th days, respectively. In group 2, it was 80.3 ± 5.9 and 84.6 ± 4.4. After treatment FOS levels were significantly higher in group 1 for days 3 and 7. (P < 0.05)ConclusionMethods of treatment with multiple molecules should be developed for complex diseases, not single molecule therapy. In this sense, this study is very important as it will bring a new perspective to the scientific world. With the treatment mentioned in the current study; It is important in terms of making a new prophylaxis and therapeutic plan for Covid-19 MESHD. It is thought that it will be unique in terms of creating a treatment plan with low potential for natural and non-synthetic side effects instead of using toxic and side effects products.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.